News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Genmab A/S Announces Pipeline and Technology Update
April 21, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
COPENHAGEN, Denmark, April 21, 2010 (GLOBE NEWSWIRE) -- Summary: Genmab has announced a new pre-clinical antibody program, HuMax-cMet, as well as a novel next generation antibody technology.
Twitter
LinkedIn
Facebook
Email
Print
Preclinical
Europe
MORE ON THIS TOPIC
ALS
ALS Community Petitions FDA To Reconsider BrainStorm’s NurOwn, Pointing to Recent Survival Data
July 8, 2025
·
3 min read
·
Heather McKenzie
Immunology and inflammation
Jasper Crashes as Compromised Drug Lot Confounds Urticaria Study
July 8, 2025
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Cogent Jumps on Positive Mid-Stage Mastocytosis Data and NDA Plans
July 7, 2025
·
1 min read
·
Dan Samorodnitsky
Drug Development
5 Second-Half Biopharma Milestones To Watch
July 7, 2025
·
8 min read
·
Tristan Manalac
